Melanoma Trial, Recruiting NCT05231655 Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT05231655
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged over 16 who have been diagnosed with, or are suspected to have, a solid cancer (a tumour that forms in an organ or tissue, not blood) and who are scheduled to have surgery, a biopsy, a fluid sample taken, or a procedure to remove bladder tumour tissue (TURBT)
  • People who are willing to donate a small piece of fresh tumour tissue collected during their procedure that is not needed for diagnostic testing
  • People who are willing to donate a 9ml blood sample (roughly two teaspoons)
  • People who are able to read and sign a consent form agreeing to take part
  • People whose cancer has come back after previous treatment, either in the same area or in another part of the body
  • People whose cancer did not respond to previous treatment and has continued to grow
  • People who have received treatment given before their main surgery or procedure (called neoadjuvant therapy)
  • People who have previously received chemotherapy, targeted therapy, immunotherapy, hormone therapy, or radiotherapy for their cancer

Who may not be able to join:

  • People who have a known diagnosis of a blood-borne virus, including Hepatitis B, Hepatitis C, or HIV, as the research laboratories are not equipped with the safety facilities needed to handle samples containing these viruses
  • People who currently have an active COVID-19 infection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sarah Danson, PhD, FRCP, University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust

Phone: +44 114 215 9098

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Registry
ClinicalTrials.gov
Start date
7 July 2021
Est. completion
1 January 2026

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Functional drug screen

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov